By Digifin Pty Ltd · About this coverage
Key Points
- Cohort 3 Day 28: one CR in MCL and one PR in CLL among four newly evaluable patients
- BTKi combination cohort now seven evaluable patients, all previously progressed on BTKi
- Phase 1b pooled ORR 75% across 55 patients; Cohort 3 ORR 71% (n=7)
- Enrolment ongoing at ten US and five Australian sites
About Imugene (ASX:IMU)
Imugene Limited is an ASX-listed clinical-stage biotechnology company developing allogeneic CAR T cell therapies for blood cancers, with lead candidate azer-cel targeting CD19.
Imugene (ASX:IMU) reported updated Day 28 data from the BTKi combination cohort of its Phase 1b azer-cel (azercabtagene zapreleucel) basket study, adding one Complete Response in Mantle Cell Lymphoma and one Partial Response in Chronic Lymphocytic Leukemia.
Four further Cohort 3 patients reached Day 28: besides the CR and PR, one patient with Richter's Transformation (DLBCL/RT) had Stable Disease and one MCL patient had Progressive Disease, taking Cohort 3 to seven evaluable patients. All enrolled patients had previously progressed on BTKi therapy. Across the Phase 1b study, azer-cel has shown a 75% overall response rate in 55 evaluated patients, including 68% ORR in CAR T-relapsed/refractory DLBCL (Cohort 1, n=22), 81% ORR in CAR T-naive patients (Cohort 2, n=26), and 71% ORR in the BTKi combination cohort (Cohort 3, n=7). Enrolment continues across ten US and five Australian sites. The release does not present duration of response or survival endpoints for the new patients.
Source: Imugene Limited (ASX:IMU), 5 October 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.